Evidence map›Paper›PMID 39997463›Full record

ArticleInfectious disease reports2025

Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital.

Virginia Di Bari, Carlotta Cerva, Raffaella Libertone, Serena Maria Carli, Maria Musso, Delia Goletti, Alessandra Aiello, Antonio Mazzarelli, Angela Cannas, Giulia Matusali and 3 more

Abstract read
In one paragraph

Article in Infectious disease reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Virginia Di BariRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.ORCID 0000-0002-3949-9705
Carlotta CervaRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.
Raffaella LibertoneRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.
Serena Maria CarliRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.
Maria MussoRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.
Delia GolettiTranslational Research Unit, National Institute for Infectious Diseases (INMI) "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.ORCID 0000-0001-8360-4376
Alessandra AielloTranslational Research Unit, National Institute for Infectious Diseases (INMI) "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.ORCID 0000-0003-2681-9383
Antonio MazzarelliMicrobiology and Bio-Repository, National Institute for Infectious Diseases (INMI) "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.ORCID 0000-0001-6285-4368
Angela CannasMicrobiology and Bio-Repository, National Institute for Infectious Diseases (INMI) "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.
Giulia MatusaliLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.ORCID 0000-0002-2948-4243
Fabrizio PalmieriRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.ORCID 0000-0001-8184-6291
Gina GualanoRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.
On Behalf Of The Tb-Inmi Working Group

Funding

Compagnia Italiana Surgelati S.p.A. Pro- 234 getto "Spallanzani Porte Aperte" grant number 62/2022Italian Ministry of Health grant Ricerca Corrente IRCCS, 232 Research line 4; project no. 4 Tuberculosis and grant Ricerca Finalizzata COVID-2020-12371675
6 · The paper itself

Abstract

BACKGROUND/

objectivesTuberculosis (TB) remains a major global health issue, further complicated by the COVID-19 pandemic. This study assesses the clinical outcomes of TB-COVID-19-coinfected patients compared to those with TB disease alone at an Italian infectious disease hospital during the pandemic's first two years.

methodsRetrospective data analysis was conducted on TB patients hospitalized from March 2020 to June 2022. Data included demographics, comorbidities, clinical characteristics, and outcomes. Coinfection was defined as concurrent TB disease and SARS-CoV-2 infection. Statistical methods included Fisher's exact test and Mann-Whitney statistics.

resultsOf 267 TB patients, 25 (9.4%) had concurrent COVID-19 infection. The TB-COVID-19 group showed higher rates of diabetes and cough. Acute respiratory failure was more prevalent in coinfected patients (odds ratio, 5.99), and coinfection was associated with worse outcomes compared to TB alone (odds ratio, 0.15). Despite similar socio-demographic factors, the coexistence of TB and COVID-19 led to exacerbated respiratory failure and increased mortality.

conclusionsCoinfection with TB and COVID-19 significantly increases the risk of acute respiratory failure and poor outcomes. Clinicians should be aware of this risk, especially in patients with pulmonary involvement. Although specific protocols are unavailable, prompt diagnosis and management may enhance outcomes. Additional research is necessary to understand the long-term effects of TB-COVID-19 coinfection, particularly as COVID-19 becomes endemic.

Indexed as

COVID-19COVID-19 severitySARS-CoV-2TB-COVID-19 coinfectionTB diseaseTB severitytuberculosis

Identifiers

PMID39997463
PMCPMC11855733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.